News/ News/ R&D FDA fast tracks Bayer’s oral anticoagulant asundexian Phil Taylor anticoagulant, asundexian, Bayer, Bristol-Myers Squibb, cardiology, Johnson & Johnson, milvexian, stroke 0 Comment The FDA has granted fast-track status to Bayer’s oral Factor Xia inhibitor asundexian, which is in phase 2 Share X FDA fast tracks Bayer’s oral anticoagulant asundexian https://pharmaphorum.com/news/fda-fast-tracks-bayers-oral-anticoagulant-asundexian/